Glucose-dependent insulinotropic polypeptide analogues and their therapeutic potential for the treatment of obesity-diabetes

2003 ◽  
Vol 308 (2) ◽  
pp. 207-213 ◽  
Author(s):  
Victor A. Gault ◽  
Peter R. Flatt ◽  
Finbarr P.M. O’Harte
Keyword(s):  
Therapeutic Potential ◽  
Treatment Of Obesity

scholarly journals Studies on Analysis of Antioxidant and Enzyme Inhibitory Activity of Vitex negundo Linn.

2017 ◽  
Vol 9 (6) ◽  
Author(s):  
Ved Prakash ◽  
Shelly Rana ◽  
Anand Sagar
Keyword(s):  
Urease Activity ◽  
Therapeutic Potential ◽  
Radical Scavenging Activity ◽  
Scientific Evidence ◽  
Radical Scavenging ◽  
Reducing Power ◽  
Vitex Negundo ◽  
Leaf Extracts ◽  
Treatment Of Obesity ◽  
Dpph Radical Scavenging

The current study was designed to investigate the leaf extracts of Vitex negundo Linn. for their antioxidant and enzyme inhibitory (α-amylae and urease) activity. The antioxidant capacity of the different extracts (methanol, acetone and aqueous) of this plant was evaluated by DPPH (1,1-diphenyl-2-picrylhydrazyl) and reducing power tests. The plant exhibited good DPPH radical scavenging activity and moderate reducing power potential Further, all the extracts of V. negundo were reported to possess good anti-alpha amylase and anti-urease activity of greater than 50% in all the solvents used at a concentration of 1 mg/mL. Thus the study provided scientific evidence to the traditional uses of this plant in the treatment of obesity, diabetes, ulcers, kidney stones etc. Therefore, the leaf extracts of this plant can be selected for further investigation to determine their therapeutic potential.

scholarly journals Elaiophylin reduces body weight and lowers glucose levels in obese mice by activating AMPK

2021 ◽  
Vol 12 (11) ◽  
Author(s):  
Ruoxuan Bao ◽  
Yongmei Meng ◽  
Haibo Zhang ◽  
Chen Yang ◽  
Wei Li ◽  
...  
Keyword(s):  
Body Weight ◽  
Chronic Diseases ◽  
Therapeutic Potential ◽  
In Vivo Studies ◽  
Pharmacological Intervention ◽  
Obese Mouse ◽  
Acid Oxidation ◽  
Dependent Manner ◽  
Glucose Levels ◽  
Treatment Of Obesity

AbstractObesity is an epidemic affecting 13% of the global population and increasing the risk of many chronic diseases. However, only several drugs are licensed for pharmacological intervention for the treatment of obesity. As a master regulator of metabolism, the therapeutic potential of AMPK is widely recognized and aggressively pursued for the treatment of metabolic diseases. We found that elaiophylin (Ela) rapidly activates AMPK in a panel of cancer-cell lines, as well as primary hepatocytes and adipocytes. Meanwhile, Ela inhibits the mTORC1 complex, turning on catabolism and turning off anabolism together with AMPK. In vitro and in vivo studies showed that Ela does not activate AMPK directly, instead, it increases cellular AMP/ATP and ADP/ATP ratios, leading to AMPK phosphorylation in a LKB1-dependent manner. AMPK activation induced by Ela caused changes in diverse metabolic genes, thereby promoting glucose consumption and fatty acid oxidation. Importantly, Ela activates AMPK in mouse liver and adipose tissue. As a consequence, it reduces body weight and blood glucose levels and improves glucose and insulin tolerance in both ob/ob and high-fat diet-induced obese mouse models. Our study has identified a novel AMPK activator as a candidate drug for the treatment of obesity and its associated chronic diseases.

scholarly journals Analysis of Achyranthes aspera L. extracts for their α-Amylase and urease inhibitory activities

2021 ◽  
Vol 11 (2) ◽  
pp. 108-112
Author(s):  
Ved Prakash ◽  
Anand Sagar
Keyword(s):  
Plant Extracts ◽  
Inhibitory Activity ◽  
Therapeutic Potential ◽  
Scientific Evidence ◽  
Herbal Medicines ◽  
Achyranthes Aspera ◽  
Whole Plant ◽  
Intestinal Infections ◽  
Treatment Of Obesity ◽  
Urease Inhibitory

Plant products have served as a major source of useful drugs for centuries and about half of the pharmaceuticals in use today are derived from these natural products. The efficacy and safety of herbal medicines have attracted the attention of scientists towards medicinal plants research. The present study was designed to investigate the whole plant extracts of Achyranthes aspera L. for their anti-enzyme (α-amylae and urease) activity. All the extracts of A. aspera were reported to show good alpha-amylase and urease inhibitory activity of greater than 50% in all the solvents used at a concentration of 1 mg/mL. α- amylase inhibition ranged from 17.66±0.10-69.90±0.50% whereas urease inhibitory activity ranged from 18.60±0.50 to 79.90±0.50% suggesting a strong α- amylase and urease inhibitory effects of this plant. Thus the study provided scientific evidence to the traditional uses of this plant in the treatment of obesity, diabetes, ulcers, kidney stones intestinal infections etc. Therefore, the whole plant extracts of A. aspera can be selected for further investigation to find their therapeutic potential. Keywords: Achyranthes aspera, plant extracts, α-Amylase, Urease

1011-P: Therapeutic Potential of Novel Combination of a Long-Acting Glucagon Analog (HM15136) and Antidiabetic Drugs for the Treatment of Obesity

Diabetes ◽  
2019 ◽  
Vol 68 (Supplement 1) ◽  
pp. 1011-P
Author(s):  
YOUNG JIN PARK ◽  
JONG SUK LEE ◽  
JUNG KUK KIM ◽  
DAEJIN KIM ◽  
YOUNG HOON KIM ◽  
...  
Keyword(s):  
Therapeutic Potential ◽  
Antidiabetic Drugs ◽  
Treatment Of Obesity ◽  
Long Acting

scholarly journals Therapeutic potential of histamine H3 receptor agonist for the treatment of obesity and diabetes mellitus

2006 ◽  
Vol 103 (37) ◽  
pp. 13866-13871 ◽  
Author(s):  
R. Yoshimoto ◽  
Y. Miyamoto ◽  
K. Shimamura ◽  
A. Ishihara ◽  
K. Takahashi ◽  
...  
Keyword(s):  
Diabetes Mellitus ◽  
Receptor Agonist ◽  
Therapeutic Potential ◽  
Histamine H3 Receptor ◽  
H3 Receptor ◽  
Obesity And Diabetes ◽  
Treatment Of Obesity ◽  
Histamine H3

scholarly journals Isolation of Monovalerianester A, an Inhibitor of Fat Accumulation, from Valeriana Fauriei

2015 ◽  
Vol 10 (8) ◽  
pp. 1934578X1501000
Author(s):  
Keiji Yuki ◽  
Mariko Ikeda ◽  
Shosuke Yoshida ◽  
Osamu Ohno ◽  
Kiyotake Suenaga ◽  
...  
Keyword(s):  
Crude Extract ◽  
Aqueous Ethanol ◽  
Therapeutic Potential ◽  
Inhibitory Effects ◽  
Chromatographic Purification ◽  
Fat Accumulation ◽  
Treatment Of Obesity

The rhizomes and roots of Valeriana fauriei were extracted with 80% aqueous ethanol. This extract was found to exhibit potent inhibitory effects on fat accumulation in 3T3-L1 murine adipocytes. After several steps of chromatographic purification, we succeeded in identifying monovalerianester A as an inhibitor of fat accumulation. Thus, monovalerianester A and the crude extract of the rhizomes and roots of V. fauriei may have therapeutic potential for the treatment of obesity.

scholarly journals Targeting the Endocannabinoid CB1 Receptor to Treat Body Weight Disorders: A Preclinical and Clinical Review of the Therapeutic Potential of Past and Present CB1 Drugs

Biomolecules ◽  
2020 ◽  
Vol 10 (6) ◽  
pp. 855 ◽  
Author(s):  
Thomas Murphy ◽  
Bernard Le Foll
Keyword(s):  
Body Weight ◽  
Therapeutic Potential ◽  
Treatment Options ◽  
Endocannabinoid System ◽  
Cb1 Receptor ◽  
Obese Subjects ◽  
Treatment Of Obesity ◽  
Psychiatric Side Effects ◽  
Preclinical And Clinical Studies ◽  
The Impact

Obesity rates are increasing worldwide and there is a need for novel therapeutic treatment options. The endocannabinoid system has been linked to homeostatic processes, including metabolism, food intake, and the regulation of body weight. Rimonabant, an inverse agonist for the cannabinoid CB1 receptor, was effective at producing weight loss in obese subjects. However, due to adverse psychiatric side effects, rimonabant was removed from the market. More recently, we reported an inverse relationship between cannabis use and BMI, which has now been duplicated by several groups. As those results may appear contradictory, we review here preclinical and clinical studies that have studied the impact on body weight of various cannabinoid CB1 drugs. Notably, we will review the impact of CB1 inverse agonists, agonists, partial agonists, and neutral antagonists. Those findings clearly point out the cannabinoid CB1 as a potential effective target for the treatment of obesity. Recent preclinical studies suggest that ligands targeting the CB1 may retain the therapeutic potential of rimonabant without the negative side effect profile. Such approaches should be tested in clinical trials for validation.

Sign in / Sign up

Export Citation Format

Share Document